myaccord
douglas pharmaceuticals limited - mycophenolate mofetil 250mg; - capsule - 250 mg - active: mycophenolate mofetil 250mg excipient: croscarmellose sodium gelatin hyprolose indigo carmine iron oxide red iron oxide yellow magnesium stearate microcrystalline cellulose povidone purified talc sodium laurilsulfate tekprint black sw-9008 titanium dioxide water - myaccord is indicated for the prophylaxis of acute organ rejection in patients receiving allogeneic renal transplants.
myaccord
douglas pharmaceuticals limited - mycophenolate mofetil 500mg; - film coated tablet - 500 mg - active: mycophenolate mofetil 500mg excipient: croscarmellose sodium hyprolose magnesium stearate microcrystalline cellulose opadry purple 03b50110 povidone purified talc - for the prophylaxis of acute organ rejection in patients receiving allogeneic renal transplants.
ceftriaxone (douglas)
douglas pharmaceuticals limited - ceftriaxone sodium 1079.3mg (present as 1.193g ceftriaxone na*3.5h2o. eq 1.0793g of ceftriaxone na anhyd or 1g ceftriaxone anhyd) - powder for injection - 1000 mg - active: ceftriaxone sodium 1079.3mg (present as 1.193g ceftriaxone na*3.5h2o. eq 1.0793g of ceftriaxone na anhyd or 1g ceftriaxone anhyd)
ceftriaxone (douglas)
douglas pharmaceuticals limited - ceftriaxone sodium 2158.6mg (present as 2.386g ceftriaxone na*3.5h2o. eq 2.158g of ceftriaxone na anhyd or 2g ceftriaxone anhyd) - powder for injection - 2000 mg - active: ceftriaxone sodium 2158.6mg (present as 2.386g ceftriaxone na*3.5h2o. eq 2.158g of ceftriaxone na anhyd or 2g ceftriaxone anhyd)
ceftriaxone (douglas)
douglas pharmaceuticals limited - ceftriaxone sodium 269.9mg (present as 0.298g ceftriaxone na*3.5h2o. eq 0.269g of ceftriaxone na anhyd or 0.25g ceftriaxone anhy) - powder for injection - 250 mg - active: ceftriaxone sodium 269.9mg (present as 0.298g ceftriaxone na*3.5h2o. eq 0.269g of ceftriaxone na anhyd or 0.25g ceftriaxone anhy)
ceftriaxone (douglas)
douglas pharmaceuticals limited - ceftriaxone sodium 539.7mg (present as 0.5965g ceftriaxone na*3.5h2o. eq 0.53965g of ceftriax na anh or 0.5g ceftriaxone anhyd) - powder for injection - 500 mg - active: ceftriaxone sodium 539.7mg (present as 0.5965g ceftriaxone na*3.5h2o. eq 0.53965g of ceftriax na anh or 0.5g ceftriaxone anhyd)
diclax sr
douglas pharmaceuticals limited - diclofenac sodium 100mg; ; - modified release tablet - 100 mg - active: diclofenac sodium 100mg excipient: diethyl phthalate ethylcellulose hypromellose iron oxide red iron oxide yellow macrogol 4000 magnesium stearate povidone purified talc stearic acid titanium dioxide
diclax sr
douglas pharmaceuticals limited - diclofenac sodium 75mg; ; - modified release tablet - 75 mg - active: diclofenac sodium 75mg excipient: diethyl phthalate ethylcellulose hypromellose iron oxide red iron oxide yellow macrogol 4000 magnesium stearate povidone purified talc stearic acid titanium dioxide
fintral
douglas pharmaceuticals limited - finasteride 5mg; - tablet - 5 mg - active: finasteride 5mg excipient: hypromellose macrogol 8 stearate type 1 sodium starch glycollate type a lactose monohydrate magnesium stearate microcrystalline cellulose sodium laurilsulfate starch - fintral is indicated for the treatment and control of benign prostatic hyperplasia (bph) and for the prevention of urologic events to; · reduce the risk of acute urinary retention · reduce the risk of surgery including transuretheral resection of the prostate (turp) and prostatectomy fintral causes regression of the enlarged prostate, improved urinary flow and improves the symptoms associated with bph. patients with enlarged prostate are the appropriate candidates for therapy with fintral.
ralicrom
douglas pharmaceuticals limited - sodium cromoglicate 100mg; ; ; ; - capsule - 100 mg - active: sodium cromoglicate 100mg excipient: gelatin black ink 1014/ sw-9008 - for chronic inflammatory conditions such as proctitis, ulcerative colitis and proctocolitis, and for use in the treatment of food allergic disease.